GHK-Cu: Mechanism, Evidence, and Dosing Protocols

Research disclaimer: GHK-Cu is sold for research purposes only and is not intended for human consumption. The information below is drawn from published scientific literature.

Evidence Tier

Strong in vitro and animal data across multiple decades. Human clinical evidence for topical wound healing and skin applications. Systemic (injection) evidence is primarily animal. The topical human evidence is among the most direct of any peptide in this series.

GHK-Cu has been studied since the 1970s, when Loren Pickart first identified it as a growth factor present in human plasma. It is one of the oldest and most extensively published peptides in this review series, with a bibliography spanning five decades.

What Is GHK-Cu?

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a tripeptide-copper complex found naturally in human plasma, saliva, and urine. The peptide Gly-His-Lys has an extraordinarily high affinity for copper(II) ions, forming a stable complex that is the biologically active form.

Plasma GHK-Cu concentration falls dramatically with age: approximately 200 ng/mL at age 20, declining to roughly 80 ng/mL by age 60 — a reduction of more than 60% by conventional measurement. When the intracellular concentration (where GHK-Cu concentrates in copper-transporting roles) is considered, the age-related decline is estimated at approximately 1,000-fold.

This is not a trace molecule. GHK-Cu levels in young adults are high enough to participate in meaningful biological signalling. The age-related collapse in concentration is considered a driver of the well-documented decline in wound healing speed, skin quality, and systemic repair capacity with advancing age.

Mechanism of Action

Copper-Dependent Gene Activation (Primary)

GHK-Cu’s most comprehensively studied mechanism is the activation of a broad set of genes involved in tissue repair, antioxidant defence, DNA repair, and tumour suppression. Loren Pickart’s group has documented activation of over 30 such genes in cell culture and animal models.

Key gene families upregulated by GHK-Cu:

• TGF-β (Transforming Growth Factor Beta): Primary driver of collagen and proteoglycan synthesis
• VEGF: Angiogenesis and wound vascularity
• Antioxidant enzymes: Superoxide dismutase, catalase, glutathione S-transferase
• DNA repair genes: Including genes involved in base excision repair
• Tumour suppressor genes: Including BRCA1/2 pathway components in some studies

The breadth of this gene activation — spanning repair, antioxidant, and tumour suppression pathways simultaneously — is unusual and may explain why GHK-Cu has documented effects across such disparate biological processes.

Copper Transport and Bioavailability

Copper is an essential cofactor for many enzymes including cytochrome c oxidase (mitochondrial), superoxide dismutase, and lysyl oxidase (collagen crosslinking). GHK-Cu may function partly as a copper delivery molecule, ensuring that copper-dependent enzymes have adequate cofactor supply in tissues where copper is limiting. As endogenous GHK-Cu declines with age, this copper-shuttling function may also decline.

Anti-inflammatory Signalling

GHK-Cu downregulates NF-κB and reduces production of inflammatory cytokines (IL-1β, TNF-α, IL-6). The anti-inflammatory mechanism is relevant both locally (skin, wounds) and potentially systemically. This positions GHK-Cu within the growing literature on anti-inflammatory interventions for longevity.

Proteasome Activation

Several studies report that GHK-Cu stimulates proteasome activity — the cellular protein degradation system that clears misfolded and damaged proteins. Proteasome function declines with age and impaired protein clearance is a driver of several neurodegenerative diseases. GHK-Cu’s effect on the proteasome is an underappreciated mechanism.

What the Evidence Actually Shows

Wound Healing (Human Clinical)

Multiple human studies confirm that topical GHK-Cu accelerates wound healing compared to controls. Studies cover chronic wounds, post-surgical wounds, and acute skin injuries. Measured outcomes include: time to closure, granulation tissue formation, and collagen density in healed tissue. This is the strongest human evidence in the GHK-Cu literature.

Skin Quality (Human Clinical)

Cosmetic dermatology trials — some double-blind, placebo-controlled — show improvements in skin thickness, elasticity, collagen density, and fine line reduction with topical GHK-Cu at concentrations of 0.1–2%. These are real clinical trials with quantitative endpoints (skin ultrasound, profilometry), not subjective reports.

Hair Growth

Animal and preliminary human data show GHK-Cu stimulates hair follicle activity and reduces hair loss. The mechanism involves stem cell activation in the hair follicle bulge. Some commercial hair loss products incorporate GHK-Cu; the evidence base for this application is moderate.

Anti-tumour Activity in Animal Models

Multiple animal studies show reduced tumour formation and growth in GHK-Cu-treated animals. The proposed mechanisms involve tumour suppressor gene activation and enhanced immune surveillance. This should be interpreted cautiously — these are animal models and the translation to human cancer prevention is completely unestablished.

Systemic Effects (Animal)

Subcutaneous GHK-Cu in animal models produces systemic anti-inflammatory effects, DNA repair enhancement, and tissue repair improvements beyond the injection site. Whether subcutaneous injection in humans produces meaningful systemic effects is not established.

What Is Not Established

• Systemic effects from topical application — skin penetration is demonstrated, systemic levels from topical are uncertain
• Whether subcutaneous injection produces systemic benefits beyond what topical application achieves
• Effective human dose for systemic gene activation via injection
• Long-term safety of systemic GHK-Cu administration
• Tumour suppression in humans — animal data only

Dosing Protocols (Research Context)

Topical (Best Evidence)

DMSO enhances skin penetration significantly. When using DMSO-based preparations, ensure skin is thoroughly clean before application — DMSO will carry any surface contaminants transdermally.

Systemic Injection

Reconstitution: GHK-Cu 50 mg vial + 10 mL bacteriostatic water → 5 mg/mL. A 1 mg dose = 0.2 mL = 20 units on a U-100 syringe.

Storage: Lyophilised: −20°C, stable 24+ months. Light-sensitive — store in dark container. Reconstituted: refrigerate 2–8°C, use within 2 weeks. The copper complex is more susceptible to degradation than the free peptide.

Summary

GHK-Cu has the broadest gene-activation profile of any compound in this review series — spanning tissue repair, antioxidant defence, DNA repair, and tumour suppression — and the most direct human clinical evidence in the longevity peptide category for its topical applications. The 1,000-fold age-related decline in endogenous levels provides a compelling rationale for supplementation. The topical route is where the evidence is; the systemic route is where the biology suggests greater potential but where human data is lacking. For researchers new to peptides, GHK-Cu topical is the most evidence-grounded entry point in the longevity category.

See also: GHK-Cu data page · Longevity Foundation Stack · Beginner Stack: BPC-157 + GHK-Cu